Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma

Inclusion Criteria: * 18 years of age or older * Histologically documented diagnosis of mucosal melanoma or acral melanoma or chronically sun damaged melanoma as evidenced by solar elastosis on pathology * Patient's tumor with evidence for KIT mutation or amplification. Patient tumors that already have documented mutations or amplification do not have to have tissue submitted again for analysis to confirm eligibility * Have failed, progressed, or not been able to tolerate other tyrosine kinase inhibitors including but not limited to imatinib mesylate, sunitinib or dasatinib treatment. * At least one measurable site of disease * ECOG Performance Status 0, 1 or 2 * Adequate organ function as outlined in the protocol * Negative pregnancy test for female patients of childbearing potential Exclusion Criteria: * Patient has received any other investigational agents within 28 days of first day of study drug dosing unless the disease is rapidly progressing * Patient is \< 5 years free of another primary malignancy except: if the other primary malignancy is not currently clinically significant nor requiring active intervention, or if other primary malignancy is a basal cell skin cancer or a cervical carcinoma in situ * Female patients who are pregnant or breast-feeding * Patient has a severe and/or uncontrolled medical disease * Patient has a rare hereditary problem of galactose intolerance, severe lactase deficiency or of glucose-galactose malabsorption * Patient with electrolyte …